Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
Canada
0
Australia
0
South Africa
Annual Reports
NA
0
FDF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. Calcort
2. Dezacor
3. Emflaza
4. Zamene
1. 14484-47-0
2. Azacort
3. Calcort
4. Oxazacort
5. Flantadin
6. Emflaza
7. Cortax
8. Deflan
9. Mdl 458
10. Mdl-458
11. L-5458
12. Kr5yz6ae4b
13. Mdl458
14. Dezacor
15. Lantadin
16. Dsstox_cid_378
17. Dsstox_rid_75552
18. Dsstox_gsid_20378
19. 2-((6ar,6bs,7s,8as,8bs,11ar,12as,12bs)-7-hydroxy-6a,8a,10-trimethyl-4-oxo-1,2,4,6a,6b,7,8,8a,11a,12,12a,12b-dodecahydro-8bh-naphtho[2',1':4,5]indeno[1,2-d]oxazol-8b-yl)-2-oxoethyl Acetate
20. Deflazacortum
21. Decortil
22. Deflanil
23. Enzocort
24. Deflazacort (calcort)
25. 2-[(4ar,4bs,5s,6as,6bs,9ar,10as,10bs)-5-hydroxy-4a,6a,8-trimethyl-2-oxo-2,4a,4b,5,6,6a,9a,10,10a,10b,11,12-dodecahydro-6bh-naphtho[2',1':4,5]indeno[1,2-d][1,3]oxazol-6b-yl]-2-oxoethyl Acetate
26. Cas-14484-47-0
27. Dl-458-it
28. Unii-kr5yz6ae4b
29. Deflazacortum [inn-latin]
30. Deflazacort [usan:inn:ban]
31. Einecs 238-483-7
32. Emflaza (tn)
33. Mfcd00866106
34. Deflazacort [mi]
35. Deflazacort [inn]
36. Deflazacort (usan/inn)
37. Deflazacort [usan]
38. Schembl4018
39. Deflazacort [mart.]
40. Deflazacort [usp-rs]
41. Deflazacort [who-dd]
42. Dl-458it
43. Gtpl9477
44. Chembl1201891
45. Dtxsid9020378
46. Deflazacort, >=98% (hplc)
47. Deflazacort [orange Book]
48. Chebi:135720
49. Hms3714d15
50. Bcp08474
51. Zinc4212809
52. Tox21_112506
53. Tox21_301415
54. Bbl036672
55. S1888
56. Stl559051
57. Akos015895199
58. Tox21_112506_1
59. Ccg-220817
60. Db11921
61. Ks-1158
62. Ncgc00255189-01
63. Ncgc00263521-01
64. 11beta,21-dihydroxy-2'-methyl-5'betah-pregna-1,4-dieno(17,16-d)oxazole-3,20-dione 21-acetate
65. Hy-13609
66. Deflazacort 100 Microg/ml In Acetonitrile
67. D4523
68. D03671
69. T70289
70. Ab01274724-01
71. Ab01274724_02
72. 484d470
73. Q779118
74. Q-101371
75. 3-amino-3-(4-chloro-3-nitro-phenyl)-propionicacid
76. Deflazacort, United States Pharmacopeia (usp) Reference Standard
77. 11b,21-dihydroxy-2'-methyl-5'bh-pregna-1,4-dieno[17,16-d]oxazole-3,20-dione 21-acetate
78. (11beta,16beta)-21-(acetyloxy)-11-hydroxy-2'-methyl-5'h-pregna-1,4-dieno(17,16-d)oxazole-3,20-dione
79. [2-[(1s,2s,4r,8s,9s,11s,12s,13r)-11-hydroxy-6,9,13-trimethyl-16-oxo-5-oxa-7-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-6,14,17-trien-8-yl]-2-oxoethyl] Acetate
80. 11.beta.,21-dihydroxy-2'-methyl-5'.beta.h-pregna-1,4-dieno(17,16-d)oxazole-3,20-dione 21-acetate
81. 2-((6ar,6bs,7s,8as,8bs,11ar,12as,12bs)-7-hydroxy-6a,8a,10-trimethyl-4-oxo-2,4,6a,6b,7,8,8a,8b,11a,12,12a,12b-dodecahydro-1h-naphtho[2',1':4,5]indeno[1,2-d]oxazol-8b-yl)-2-oxoethyl Acetate
82. 5'-beta-h-pregna-1,4-dieno(17,16-d)oxazole-3,20-dione, 11-beta,21-dihydroxy-2'-methyl-, 21-acetate
83. 5'h-pregna-1,4-dieno(17,16-d)oxazole-3,20-dione, 21-(acetyloxy)-11-hydroxy-2'-methyl-, (11.beta.,16.beta.)-
84. 5'h-pregna-1,4-dieno(17,16-d)oxazole-3,20-dione, 21-(acetyloxy)-11-hydroxy-2'-methyl-, (11beta,16beta)-
| Molecular Weight | 441.5 g/mol |
|---|---|
| Molecular Formula | C25H31NO6 |
| XLogP3 | 2 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 4 |
| Exact Mass | 441.21513771 g/mol |
| Monoisotopic Mass | 441.21513771 g/mol |
| Topological Polar Surface Area | 102 Ų |
| Heavy Atom Count | 32 |
| Formal Charge | 0 |
| Complexity | 996 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 8 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Deflazacort is indicated for the treatment of Duchenne Muscular Dystrophy (DMD) in patients 2 years of age and older.
Deflazacort exerts anti-inflammatory activity in DMD, likely improving various symptoms, including muscle weakness and cardiorespiratory symptoms in addition to delaying their onset. This allows for an increased quality of life and prevents the necessity for surgical procedures, such as those for scoliosis, which is associated with DMD. Studies showed significant preservation of muscle mass in patients generally treated with 0.9 mg/kg/day of deflazacort compared to a control group. The following findings are based on clinical studies using deflazacort on a long term basis: **Effects on muscle strength** At age 16, individuals treated with long-term deflazacort had 63 4% score in muscle strength compared to a mean muscle strength score of 31 3% for control patients. Significant improvements in climbing stairs and rising from a supine position were also seen in patients taking deflazacort. **Effects on ambulation** Ambulation was significantly higher by 12 years of age and 18 years of age in patients taking deflazacort when compared with the control group. The control group showed a mean loss of ambulation of 2 years sooner than with deflazacort treatment. **Effects on cardiac function** Mean left ventricular ejection fraction (a measure of cardiac function) was higher in patients treated with deflazacort over the long term. Preservation of cardiac function was demonstrated by a mean difference in ejection fraction of about 7%, favoring study groups taking deflazacort over control groups. **Effects on spinal alignment** Children treated with deflazacort also significantly lowered the rate and severity of scoliosis and eliminated the need for scoliosis surgery after long-term treatment.
Anti-Inflammatory Agents
Substances that reduce or suppress INFLAMMATION. (See all compounds classified as Anti-Inflammatory Agents.)
Immunosuppressive Agents
Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. (See all compounds classified as Immunosuppressive Agents.)
H02AB13
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
H - Systemic hormonal preparations, excl. sex hormones and insulins
H02 - Corticosteroids for systemic use
H02A - Corticosteroids for systemic use, plain
H02AB - Glucocorticoids
H02AB13 - Deflazacort
Absorption
Deflazacort is rapidly absorbed after oral administration with peak concentration occurring within 1-2 hours. One pharmacokinetic study determined an AUC (area under the curve) of 280 ng/ml h. The bioavailability of both the oral suspension and tablet are similar. In clinical studies, coadministration of deflazacort crushed with food or applesauce did not affect absorption or bioavailability.
Route of Elimination
Urinary excretion is the major route of deflazacort elimination, accounting for about about 70% of the excreted dose. The remainder of the dose (about 30%) is excreted in the feces. Elimination is almost completed by 24 hours post-dose. 21-deflazacort makes up about 18% of the eliminated drug in the urine.
Volume of Distribution
One study determined the volume of distribution to be 204 84 L.
Clearance
114 27 L/h, according to one noncompartmental pharmacokinetic study. The clearance of corticosteroids is enhanced in hypothyroid patients and increased in patients with hyperthyroidism. Dosing adjustments may be considered according to thyroid status. A study of corticosteroid clearance was performed in patients with a creatinine clearance of 15 mL/min or less, and determined that the active metabolite of deflazacort, 21-deflazacort was similar to that in patients with normal renal clearance.
After oral ingestion, deflazacort is deacetylated at position 21 by plasma esterases, producing the active metabolite 21-deflazacort. 21-deflazacort is then further metabolized by CYP3A4 to inactive metabolite products. Deflazacort 21-OH metabolism is extensive. The metabolite of deflazacort-21-OH is deflazacort 6-beta-OH.
The half-life of deflazacort ranges from 1.1 to 1.9 h
Deflazacort is a corticosteroid prodrug with an active metabolite, 21-deflazacort, which binds to the glucocorticoid receptor to exert anti-inflammatory and immunosuppressive effects on the body. The exact mechanism by which deflazacort exerts its therapeutic effects in patients with DMD is unknown but likely occurs via its anti-inflammatory activities.
GDUFA
DMF Review : Complete
Rev. Date : 2023-12-20
Pay. Date : 2023-11-22
DMF Number : 38936
Submission : 2023-10-05
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2021-11-05
Pay. Date : 2021-11-02
DMF Number : 24691
Submission : 2011-03-02
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 4922
Submission : 1983-03-17
Status : Inactive
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2023-07-11
Pay. Date : 2023-05-19
DMF Number : 38357
Submission : 2023-05-19
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2023-03-08
Pay. Date : 2023-03-06
DMF Number : 30313
Submission : 2016-03-02
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2021-07-28
Pay. Date : 2021-05-26
DMF Number : 35535
Submission : 2021-04-26
Status : Active
Type : II

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Date of Issue : 2025-11-20
Valid Till : 2028-11-19
Written Confirmation Number : WC-0009
Address of the Firm : Plot No. 55, 56 & 57, HSIIDC Industrial Estate, Murthal, Sonipat-131 029, Haryan...
Date of Issue : 2025-09-03
Valid Till : 2028-09-02
Written Confirmation Number : WC-0161
Address of the Firm : 385/2, Gram Pigdamber, Rau , Indore-453331, Madhya Pradesh, India
Date of Issue : 2022-06-30
Valid Till : 2025-07-02
Written Confirmation Number : WC-0161n
Address of the Firm : PLOT NO.385/2, Gram Pigdamber, Rau , Indore-453331, Madhya Pradesh, India
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]About the Company : Coral Drugs is a research-based international pharmaceutical company with over 27 years of expertise in manufacturing high-quality, affordable APIs. Headquartered in Delhi, India, ...
About the Company : Symbiotec, based in Indore, India, is a leading API manufacturer specializing in cortico-steroids and steroid-hormone APIs since 1995. Focused on R&D, sustainability, and innovatio...
About the Company : Beijing Mesochem Technology Co. Ltd., located in the Yizhuang National Economic and Technological Development Area, China, manufactures pharmaceutical chemicals, fine chemicals, an...
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
About the Company : LGM Pharma is a global leader in sourcing hard-to-find APIs and intermediates for pharmaceutical and biotech industries. LGM also operates as a full-service CDMO, offering formulat...
Gonane has API manufacturing expertise in new-age Corticosteroids, Hormones and other pharma raw materials.
About the Company : Gonane Pharma is a contract pharmaceutical company based in Gujarat, India, specializing in the manufacturing and marketing of corticosteroids, hormones, antivirals, and oncology p...
About the Company : Jai Radhe Sales, founded in 1999, is a global distributor specializing in high-quality pharmaceutical ingredients from India. It offers complete sourcing solutions, technical and r...
Tenatra connects Indian manufacturers with global buyers through active partners in Germany, Switzerland, Belgium, Spain & Turkey.
About the Company : Tenatra International was established as a proprietorship firm in 1999. It got off to a very good start, supporting clients in the United States, Mexico and Europe. As business opp...
Human Pharmalabs manufacturer of high quality corticosteroid APIs with a state of the art facility in Kalol Gandhinagar.
About the Company : Human Pharmalabs Pvt. Ltd. was founded to manufacture lifesaving critical APIs in India, pioneering the introduction of Corticosteroid APIs. The company adheres to international st...
About the Company : Mahima Life Sciences Pvt. Ltd. stands as a prominent manufacturer and exporter of Corticosteroids, APIs, and Vitamins, based in New Delhi, India, boasting a robust global presence ...

About the Company : Micro Orgo Chem is a pharmaceutical establishment, manufacturing niche Active Pharmaceutical Ingredients (API). Founded in 1992, we have a mission of providing high quality drugs t...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Deflazacort, a steroid targeting the glucocorticoid receptor, shows promise in treating Duchenne muscular dystrophy.
Lead Product(s): Deflazacort,Inapplicable
Therapeutic Area: Genetic Disease Brand Name: Kymbee
Study Phase: Approved FDFProduct Type: Steroid
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 01, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Deflazacort,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Upsher-Smith Launches KYMBEE™ Tablets for Duchenne Muscular Dystrophy Treatment
Details : Deflazacort, a steroid targeting the glucocorticoid receptor, shows promise in treating Duchenne muscular dystrophy.
Product Name : Kymbee
Product Type : Steroid
Upfront Cash : Inapplicable
December 01, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Emflaza-Generic (Deflazacort) is a Steroid drug candidate, which is currently being evaluated in Approved FDF clinical studies for the treatment of Muscular Dystrophy, Duchenne.
Lead Product(s): Deflazacort,Inapplicable
Therapeutic Area: Genetic Disease Brand Name: Emflaza-Generic
Study Phase: Approved FDFProduct Type: Steroid
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 06, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Deflazacort,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Zydus Lifesciences gets USFDA nod for Deflazacort oral suspension
Details : Emflaza-Generic (Deflazacort) is a Steroid drug candidate, which is currently being evaluated in Approved FDF clinical studies for the treatment of Muscular Dystrophy, Duchenne.
Product Name : Emflaza-Generic
Product Type : Steroid
Upfront Cash : Inapplicable
October 06, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Jaythari (deflazacort) is a corticosteroid, acts as glucocorticoid receptor agonist. It is approved for the treatment of duchenne muscular dystrophy in patients 5 years of age and older.
Lead Product(s): Deflazacort,Inapplicable
Therapeutic Area: Genetic Disease Brand Name: Jaythari
Study Phase: Approved FDFProduct Type: Steroid
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 14, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Deflazacort,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Zydus Lifesciences Receives USFDA Approval for DMD Treatment Drug
Details : Jaythari (deflazacort) is a corticosteroid, acts as glucocorticoid receptor agonist. It is approved for the treatment of duchenne muscular dystrophy in patients 5 years of age and older.
Product Name : Jaythari
Product Type : Steroid
Upfront Cash : Inapplicable
April 14, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Emflaza-Generic (deflazacort) is a corticosteroid prodrug, which acts through the glucocorticoid receptor as an agonist. It is approved for the treatment of duchenne muscular dystrophy.
Lead Product(s): Deflazacort,Inapplicable
Therapeutic Area: Genetic Disease Brand Name: Emflaza-Generic
Study Phase: Approved FDFProduct Type: Steroid
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 12, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Deflazacort,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Cranbury Receives FDA Approval for First Generic Emflaza Oral Suspension
Details : Emflaza-Generic (deflazacort) is a corticosteroid prodrug, which acts through the glucocorticoid receptor as an agonist. It is approved for the treatment of duchenne muscular dystrophy.
Product Name : Emflaza-Generic
Product Type : Steroid
Upfront Cash : Inapplicable
June 12, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Emflaza (deflazacort), a corticosteroid prodrug whose active metabolite acts as a glucocorticoid receptor agonist. It is approved for treating duchenne muscular dystrophy in patients 5 years & older.
Lead Product(s): Deflazacort,Inapplicable
Therapeutic Area: Genetic Disease Brand Name: Emflaza
Study Phase: Approved FDFProduct Type: Steroid
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 12, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Deflazacort,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Aurobindo Pharma Receives USFDA Approval for Deflazacort Tablets in Multiple Strengths
Details : Emflaza (deflazacort), a corticosteroid prodrug whose active metabolite acts as a glucocorticoid receptor agonist. It is approved for treating duchenne muscular dystrophy in patients 5 years & older.
Product Name : Emflaza
Product Type : Steroid
Upfront Cash : Inapplicable
February 12, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
FG-3019 (pamrevlumab) is a potential first-in-class antibody being developed to inhibit the activity of CTGF, a common factor in fibrotic and proliferative disorders, which is investigated for the treatment of ambulatory patients with Duchenne muscular dystrophy.
Lead Product(s): Pamrevlumab,Deflazacort
Therapeutic Area: Genetic Disease Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 29, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Pamrevlumab,Deflazacort
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : FG-3019 (pamrevlumab) is a potential first-in-class antibody being developed to inhibit the activity of CTGF, a common factor in fibrotic and proliferative disorders, which is investigated for the treatment of ambulatory patients with Duchenne muscular d...
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
August 29, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
FG-3019 (pamrevlumab) is a potential first-in-class antibody being developed to inhibit the activity of CTGF, a common factor in fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure.
Lead Product(s): Pamrevlumab,Deflazacort
Therapeutic Area: Genetic Disease Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 07, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Pamrevlumab,Deflazacort
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : FG-3019 (pamrevlumab) is a potential first-in-class antibody being developed to inhibit the activity of CTGF, a common factor in fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction an...
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
June 07, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Pamrevlumab (FG-3019), is a potential antibody, have potential to inhibit the activity of connective tissue growth factor, a common factor in fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure.
Lead Product(s): Pamrevlumab,Deflazacort
Therapeutic Area: Genetic Disease Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 08, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Pamrevlumab,Deflazacort
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Pamrevlumab (FG-3019), is a potential antibody, have potential to inhibit the activity of connective tissue growth factor, a common factor in fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ d...
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
June 08, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
The results of this analysis adds to the body of evidence and clearly demonstrates the clinical benefit of EMFLAZA over prednisone. These results also reflect the benefit that patients experience in the real-world setting.
Lead Product(s): Deflazacort,Inapplicable
Therapeutic Area: Genetic Disease Brand Name: Emflaza
Study Phase: Approved FDFProduct Type: Steroid
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 24, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Deflazacort,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Results Add to Body of Evidence Confirming EMFLAZA®'s Benefit Over Prednisone
Details : The results of this analysis adds to the body of evidence and clearly demonstrates the clinical benefit of EMFLAZA over prednisone. These results also reflect the benefit that patients experience in the real-world setting.
Product Name : Emflaza
Product Type : Steroid
Upfront Cash : Inapplicable
June 24, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
This designation follows review of the Phase 2 clinical data from a single-arm trial in non-ambulatory patients with DMD, and represents recognition by the FDA that pamrevlumab has the potential to address an unmet medical need for this disease.
Lead Product(s): Pamrevlumab,Deflazacort
Therapeutic Area: Genetic Disease Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 12, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Pamrevlumab,Deflazacort
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : This designation follows review of the Phase 2 clinical data from a single-arm trial in non-ambulatory patients with DMD, and represents recognition by the FDA that pamrevlumab has the potential to address an unmet medical need for this disease.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
April 12, 2021

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CAS Number : 21269-13-6
End Use API : Deflazacort
About The Company : Huvepharma® Italia is a fast-growing global pharmaceutical company duly organized for developing, manufacturing and marketing advanced intermediates and active...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
90
PharmaCompass offers a list of Deflazacort API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Deflazacort manufacturer or Deflazacort supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Deflazacort manufacturer or Deflazacort supplier.
PharmaCompass also assists you with knowing the Deflazacort API Price utilized in the formulation of products. Deflazacort API Price is not always fixed or binding as the Deflazacort Price is obtained through a variety of data sources. The Deflazacort Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Deflazacortum manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Deflazacortum, including repackagers and relabelers. The FDA regulates Deflazacortum manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Deflazacortum API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Deflazacortum manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Deflazacortum supplier is an individual or a company that provides Deflazacortum active pharmaceutical ingredient (API) or Deflazacortum finished formulations upon request. The Deflazacortum suppliers may include Deflazacortum API manufacturers, exporters, distributors and traders.
click here to find a list of Deflazacortum suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Deflazacortum DMF (Drug Master File) is a document detailing the whole manufacturing process of Deflazacortum active pharmaceutical ingredient (API) in detail. Different forms of Deflazacortum DMFs exist exist since differing nations have different regulations, such as Deflazacortum USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Deflazacortum DMF submitted to regulatory agencies in the US is known as a USDMF. Deflazacortum USDMF includes data on Deflazacortum's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Deflazacortum USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Deflazacortum suppliers with USDMF on PharmaCompass.
A Deflazacortum written confirmation (Deflazacortum WC) is an official document issued by a regulatory agency to a Deflazacortum manufacturer, verifying that the manufacturing facility of a Deflazacortum active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Deflazacortum APIs or Deflazacortum finished pharmaceutical products to another nation, regulatory agencies frequently require a Deflazacortum WC (written confirmation) as part of the regulatory process.
click here to find a list of Deflazacortum suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Deflazacortum as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Deflazacortum API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Deflazacortum as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Deflazacortum and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Deflazacortum NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Deflazacortum suppliers with NDC on PharmaCompass.
Deflazacortum Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Deflazacortum GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Deflazacortum GMP manufacturer or Deflazacortum GMP API supplier for your needs.
A Deflazacortum CoA (Certificate of Analysis) is a formal document that attests to Deflazacortum's compliance with Deflazacortum specifications and serves as a tool for batch-level quality control.
Deflazacortum CoA mostly includes findings from lab analyses of a specific batch. For each Deflazacortum CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Deflazacortum may be tested according to a variety of international standards, such as European Pharmacopoeia (Deflazacortum EP), Deflazacortum JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Deflazacortum USP).